A comprehensive review of the clinical aspects of primary aldosteronism

Nature Reviews Endocrinology

Volumn 7, Issue 8, 2011, Pages 485-495

  Rossi, Gian Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANRENOATE POTASSIUM; CANRENONE; CAPTOPRIL; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; FLUDROCORTISONE; METOMIDATE; MINERALOCORTICOID ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM SPARING DIURETIC AGENT; RENIN INHIBITOR; SPIRONOLACTONE;

ADRENAL CORTEX ADENOMA; ADRENALECTOMY; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DOSE REDUCTION; HEART INJURY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY INJURY; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA RENIN ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT LOADING; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TERTIARY HEALTH CARE;

ADRENALECTOMY; CARDIOVASCULAR DISEASES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION;

EID: 79960844001     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.76     Document Type: Review

References (111)

1. Neves, M. F. & Schiffrin, E. L. Aldosterone: a risk factor for vascular disease. Curr. Hypertens. Rep. 5, 59-65 (2003). (Pubitemid 38898933)
2. Pu, Q., Neves, M. F., Virdis, A., Touyz, R. M. & Schiffrin, E. L. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42, 49-55 (2003). (Pubitemid 36849598)
3. Schupp, N. et al. Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists. Horm. Metab. Res. 42, 458-465 (2010).
4. Rocha, R. et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283, H1802-H1810 (2002). (Pubitemid 35217013)
5. Brilla, C. G., Maisch, B. & Weber, K. T. Myocardial collagen matrix remodelling in arterial hypertension. Eur. Heart J. 13 (Suppl. D), 24-32 (1992).
6. Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S. & Weber, K. T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. 67, 1355-1364 (1990).
7. Rossi, G. P. et al. Left ventricular systolic function in primary aldosteronism and hypertension. J. Hypertens. 16, 2075-2077 (1998). (Pubitemid 29002390)
8. Rossi, G. P. et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95, 1471-1478 (1997). (Pubitemid 27142805)
9. Rossi, G. P. et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 40, 23-27 (2002). (Pubitemid 34755974)
10. Farquharson, C. A. & Struthers, A. D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin. Sci. (Lond.) 103, 425-431 (2002). (Pubitemid 35193248)
11. Nishizaka, M. K., Zaman, M. A., Green, S. A., Renfroe, K. Y. & Calhoun, D. A. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 109, 2857-2861 (2004). (Pubitemid 38780298)
12. Taddei, S., Virdis, A., Mattei, P. & Salvetti, A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21, 929-933 (1993). (Pubitemid 23166942)
13. Muiesan, M. L. et al. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J. Hypertens. 20, 1439-1444 (2002). (Pubitemid 34925690)
14. Rizzoni, D. et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J. Am. Coll. Cardiol. 32, 985-992 (1998). (Pubitemid 28459589)
15. Halimi, J. M. & Mimran, A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J. Hypertens. 13, 1801-1802 (1995). (Pubitemid 26015820)
16. Rossi, G. P. et al. for the PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 48, 232-238 (2006).
17. Rossi, G. P. et al. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol. Metab. 19, 88-90 (2008).
18. Sechi, L. A. et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 295, 2638-2645 (2006). (Pubitemid 43882339)
19. Nishimura, M. et al. Cardiovascular complications in patients with primary aldosteronism. Am. J. Kidney Dis. 33, 261-266 (1999). (Pubitemid 29072226)
20. Takeda, R., Matsubara, T., Miyamori, I., Hatakeyama, H. & Morise, T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J. Endocrinol. Invest. 18, 370-373 (1995).
21. Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243-1248 (2005). (Pubitemid 40523144)
22. Rossi, G. P. Surgically correctable hypertension caused by primary aldosteronism. Best Pract. Res. Clin. Endocrinol. Metab. 20, 385-400 (2006). (Pubitemid 44356451)
23. Conn, J. W. in Hypertension: Pathophysiology and Treatment 768-780 (McGraw-Hill, New York, 1977).
24. Conn, J. W. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 116, 253-267 (1990).
25. Conn, J. W. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. JAMA 190, 222-225 (1964).
26. Conn, J. W. A concluding response. Arch. Intern. Med. 123, 154-155 (1969).
27. Rossi, G. P. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue? Curr. Hypertens. Rep. 6, 1-4 (2004). (Pubitemid 39359536)
28. Rossi, G. P., Pessina, A. C. & Heagerty, A. M. Primary aldosteronism: an update on screening, diagnosis and treatment. J. Hypertens. 26, 613-621 (2008). (Pubitemid 351354903)
29. Gordon, R. D., Ziesak, M. D., Tunny, T. J., Stowasser, M. & Klemm, S. A. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin. Exp. Pharmacol. Physiol. 20, 296-298 (1993). (Pubitemid 23140199)
30. Anderson, G. H. Jr, Blakeman, N. & Streeten, D. H. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J. Hypertens. 12, 609-615 (1994). (Pubitemid 24192887)
31. Gordon, R. D., Stowasser, M., Tunny, T. J., Klemm, S. A. & Rutherford, J. C. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol. 21, 315-318 (1994). (Pubitemid 24201225)
32. Abdelhamid, S. et al. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch. Intern. Med. 156, 1190-1195 (1996). (Pubitemid 26197664)
33. Brown, M. A., Cramp, H. A., Zammit, V. C. & Whitworth, J. A. Primary hyperaldosteronism: a missed diagnosis in 'essential hypertensives'? Aust. N. Z. J. Med. 26, 533-538 (1996). (Pubitemid 26279203)
34. Rossi, G. P. et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin. Endocrinol. (Oxf.) 49, 713-723 (1998). (Pubitemid 29009500)
35. Mosso, L. et al. High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension [Spanish]. Rev. Med. Chil. 127, 800-806 (1999).
36. Rayner, B. L., Opie, L. H. & Davidson, J. S. The aldosterone/renin ratio as a screening test for primary aldosteronism. S. Afr. Med. J. 90, 394-400 (2000). (Pubitemid 30303558)
37. Loh, K. C., Koay, E. S., Khaw, M. C., Emmanuel, S. C. & Young, W. F. Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J. Clin. Endocrinol. Metab. 85, 2854-2859 (2000). (Pubitemid 32269163)
38. Denolle, T. et al. What tests should be conducted for secondary arterial hypertension in hypertensive patients resistant to treatment [French]? Arch. Mal. Coeur Vaiss. 93, 1037-1039 (2000).
39. Cortés, P. et al. Excess of mineralocorticoids in essential hypertension: clinical-diagnostic approach [Spanish]. Rev. Med. Chil. 128, 955-961 (2000).
40. Nishikawa, T. & Omura, M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed. Pharmacother. 54 (Suppl. 1), 83S-85S (2000). (Pubitemid 30428896)
41. Lim, P. O., Dow, E., Brennan, G., Jung, R. T. & MacDonald, T. M. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J. Hum. Hypertens. 14, 311-315 (2000). (Pubitemid 30311512)
42. Rayner, B. L., Myers, J. E., Opie, L. H., Trinder, Y. A. & Davidson, J. S. Screening for primary aldosteronism-normal ranges for aldosterone and renin in three South African population groups. S. Afr. Med. J. 91, 594-599 (2001). (Pubitemid 32707864)
43. Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., Thakkar, R. B. & Weissmann, P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40, 892-896 (2002). (Pubitemid 35434912)
44. Schwartz, G. L., Chapman, A. B., Boerwinkle, E., Kisabeth, R. M. & Turner, S. T. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin. Chem. 48, 1919-1923 (2002). (Pubitemid 35222749)
45. Rossi, E. et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am. J. Hypertens. 15, 896-902 (2002). (Pubitemid 35168429)
46. Rossi, G. P. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293-2300 (2006). (Pubitemid 44873058)
47. Olivieri, O. et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J. Clin. Endocrinol. Metab. 89, 4221-4226 (2004). (Pubitemid 39244414)
48. Rossi, G. P., Seccia, T. M. & Pessina, A. C. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit. Rev. Clin. Lab. Sci. 44, 1-85 (2007). (Pubitemid 44973616)
49. Funder, J. W. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 3266-3281 (2008).
50. Rossi, G. P. et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 51, 1366-1371 (2008). (Pubitemid 351555951)
51. Goodfriend, T. L. & Calhoun, D. A. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 43, 518-524 (2004). (Pubitemid 38282420)
52. Rossi, G. P. et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J. Clin. Endocrinol. Metab. 93, 2566-2571 (2008). (Pubitemid 352008521)
53. Hiramatsu, K. et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med. 141, 1589-1593 (1981). (Pubitemid 12234064)
54. Rossi, G. P. et al. The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J. Hypertens. 28, 1892-1899 (2010).
55. Rossi, G. P. et al. Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension 55, 83-89 (2010).
56. Sealey, J. E. Plasma renin activity and plasma prorenin assays. Clin. Chem. 37, 1811-1819 (1991). (Pubitemid 121000617)
57. Roding, J. H., Weterings, T. & van der Heiden, C. Plasma renin activity: temperature optimum at approximately 45 degrees C. Clin. Chem. 43, 1243-1244 (1997). (Pubitemid 27297273)
58. Sealey, J. E., Gordon, R. D. & Mantero, F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol. Metab. 16, 86-91 (2005). (Pubitemid 40432456)
59. Campbell, D. J. et al. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin. Chem. 55, 867-877 (2009).
60. Mulatero, P. et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40, 897-902 (2002). (Pubitemid 35434913)
61. Stowasser, M. et al. Diagnosis and management of primary aldosteronism. J. Renin Angiotensin Aldosterone Syst. 2, 156-169 (2001). (Pubitemid 33685887)
62. Agharazii, M., Douville, P., Grose, J. H. & Lebel, M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 37, 1440-1443 (2001). (Pubitemid 34225389)
63. Castro, O. L., Yu, X. & Kem, D. C. Diagnostic value of the post-captopril test in primary aldosteronism. Hypertension 39, 935-938 (2002). (Pubitemid 34437553)
64. Irony, I., Kater, C. E., Biglieri, E. G. & Shackleton, C. H. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am. J. Hypertens. 3, 576-582 (1990). (Pubitemid 20384002)
65. Gordon, R. D., Gomez-Sanchez, C. E., Hamlet, S. M., Tunny, T. J. & Klemm, S. A. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (iha:adrenal hyperplasia) or low-renin hypertension. J. Hypertens. Suppl. 5, S103-S106 (1987). (Pubitemid 18074895)
66. Holland, O. B. et al. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 6, 717-723 (1984). (Pubitemid 15210514)
67. Rossi, G. P. et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J. Hypertens. 25, 1433-1442 (2007). (Pubitemid 46918831)
68. Rossi, G. P. et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 50, 424-431 (2007). (Pubitemid 47205795)
69. Gordon, R. D. Primary aldosteronism. J. Endocrinol. Invest. 18, 495-511 (1995).
70. Stowasser, M. et al. Diagnosis and management of primary aldosteronism. J. Renin Angiotensin Aldosterone Syst. 2, 156-169 (2001). (Pubitemid 33685887)
71. Mulatero, P. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J. Clin. Endocrinol. Metab. 89, 1045-1050 (2004). (Pubitemid 38368386)
72. Goh, B. K. et al. Primary hyperaldosteronism secondary to unilateral adrenal hyperplasia: an unusual cause of surgically correctable hypertension. A review of 30 cases. World J. Surg. 31, 72-79 (2007). (Pubitemid 46089546)
73. Rossi, G. P., Vendraminelli, R., Cesari, M. & Pessina, A. C. A thoracic mass with hypertension and hypokalaemia. Lancet 356, 1570 (2000).
74. Seccia, T. M., Fassina, A., Nussdorfer, G. G., Pessina, A. C. & Rossi, G. P. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr. Relat. Cancer 12, 149-159 (2005). (Pubitemid 40477095)
75. Rossi, G. P. et al. Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism. J. Hum. Hypertens. 7, 357-363 (1993). (Pubitemid 23243382)
76. Omura, M., Sasano, H., Fujiwara, T., Yamaguchi, K. & Nishikawa, T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 51, 350-355 (2002). (Pubitemid 34232637)
77. Fallo, F., Barzon, L., Boscaro, M. & Sonino, N. Coexistence of aldosteronoma and contralateral nonfunctioning adrenal adenoma in primary aldosteronism. Am. J. Hypertens. 10, 476-478 (1997). (Pubitemid 27195986)
78. Magill, S. B. et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J. Clin. Endocrinol. Metab. 86, 1066-1071 (2001). (Pubitemid 32322983)
79. Kloos, R. T., Gross, M. D., Francis, I. R., Korobkin, M. & Shapiro, B. Incidentally discovered adrenal masses. Endocr. Rev. 16, 460-484 (1995).
80. Mantero, F. et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J. Clin. Endocrinol. Metab. 85, 637-644 (2000).
81. Young, W. F. et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 136, 1227-1235 (2004).
82. Kempers, M. J. et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann. Intern. Med. 151, 329-337 (2009).
83. Rossi, G. P. et al. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J. Hypertens. 26, 989-997 (2008). (Pubitemid 351520987)
84. Daunt, N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 25 (Suppl. 1), S143-S158 (2005). (Pubitemid 41686069)
85. Mulatero, P. et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J. Clin. Endocrinol. Metab. 91, 2618-2623 (2006). (Pubitemid 44024627)
86. Auchus, R. J. et al. What we still do not know about adrenal vein sampling for primary aldosteronism. Horm. Metab. Res. 42, 411-415 (2010).
87. Seccia, T. M. et al. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension 53, 761-766 (2009).
88. Rossi, G. P. et al. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J. Hypertens. 24, 371-379 (2006). (Pubitemid 43348251)
89. Miotto, D. et al. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension 54, 885-889 (2009).
90. Mengozzi, G. et al. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. Clin. Chem. 53, 1968-1971 (2007). (Pubitemid 350036044)
91. Auchus, R. J. et al. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism. Ann. Surg. 249, 318-321 (2009).
92. Rossi, G. P. et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J. Clin. Endocrinol. Metab. 86, 1083-1090 (2001). (Pubitemid 32322986)
93. Rossi, G. P., Pitter, G. & Miotto, D. To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not? J. Hypertens. 25, 481-484 (2007). (Pubitemid 46071951)
94. Rossi, G. P., Pitter, G. & Miotto, D. To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not? Round 2. J. Hypertens. 25, 1518-1520 (2007). (Pubitemid 46918848)
95. Carr, C. E., Cope, C., Cohen, D. L., Fraker, D. L. & Trerotola, S. O. Comparison of sequential versus simultaneous methods of adrenal venous sampling. J. Vasc. Interv. Radiol. 15, 1245-1250 (2004). (Pubitemid 39487854)
96. Shade, R. E. & Grim, C. E. Suppression of renin and aldosterone by small amounts of DOCA in normal man. J. Clin. Endocrinol. Metab. 40, 652-658 (1975).
97. Mulatero, P. et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J. Clin. Endocrinol. Metab. 93, 1366-1371 (2008). (Pubitemid 351519734)
98. Enberg, U. et al. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. Eur. J. Endocrinol. 151, 73-85 (2004). (Pubitemid 39117367)
99. Nishimoto, K. et al. Adrenocortical zonation in humans under normal and pathological conditions. J. Clin. Endocrinol. Metab. 95, 2296-2305 (2010).
100. ClinicalTrials.gov Adrenal Vein Sampling International Study (AVIS Study) [online], http://clinicaltrials.gov/ct2/show/NCT01234220 (2011).
101. Rossi, G. P. et al. The Adrenal Vein Sampling International Study (AVIS) on the use and interpretation of adrenal vein sampling for identifying the major subtypes of primary aldosteronism: results of phase I (abstract). Presented at ENDO 2011.
102. Toniato, A., Bernante, P., Rossi, G. P., Piotto, A. & Pelizzo, M. R. Laparoscopic versus open adrenalectomy: outcome in 35 consecutive patients. Int. J. Surg. Investig. 1, 503-507 (2000).
103. Jeschke, K. et al. Laparoscopic partial adrenalectomy in patients with aldosterone-producing adenomas: indications, technique, and results. Urology 61, 69-72 (2003). (Pubitemid 36151714)
104. Meria, P., Kempf, B. F., Hermieu, J. F., Plouin, P. F. & Duclos, J. M. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J. Urol. 169, 32-35 (2003). (Pubitemid 35461542)
105. Sawka, A. M. et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann. Intern. Med. 135, 258-261 (2001). (Pubitemid 32799339)
106. Lumachi, F. et al. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am. Surg. 71, 864-869 (2005).
107. Sukor, N., Kogovsek, C., Gordon, R. D., Robson, D. & Stowasser, M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 95, 1360-1364 (2010).
108. Obara, T. et al. Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery 112, 987-993 (1992). (Pubitemid 23008223)
109. Proye, C. A. et al. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 124, 1128-1133 (1998). (Pubitemid 28555205)
110. Dietz, J. D. et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 51, 742-748 (2008). (Pubitemid 351301529)
111. Amar, L., et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56, 831-838 (2010).